Table 2 Demographics characteristics and pain-related data in the YAC cohort. Data are mean ± SD or number (%)
From: Impairment in sleep health in young adults with chronic pain: a modifiable risk factor
Variable | Total (n = 55)a | Males (n = 15) | Females (n = 39) | P value |
|---|---|---|---|---|
Age (years) | 20.29 ± 2.9 | 21.38 ± 2.6 | 19.88 ± 2.2 | 0.045 |
BMIb (kg/m2) | 24.15 ± 5.90 | 19.87 ± 2.8 | 25.41 ± 6.1 | 0.040 |
Pain duration (years) | 8.18 ± 5.35 | 6.17 ± 3.40 | 8.13 ± 5.56 | 0.569 |
Pain syndrome | ||||
 Chronic Widespread Pain/Fibromyalgia | 19 (34.5%) | 4 (26.7%) | 14 (35.9%) | ns |
 Chronic Widespread Pain: secondary | 10 (18.2%) | 1 (6.7%) | 9 (23.1%) | |
 Musculoskeletal pain | 6 (10.9%) | 2 (13.3%) | 4 (10.3%) | |
 Back Pain | 8 (14.5%) | 3 (20%) | 4 (10.3%) | |
 Neuropathic Pain Syndromes | 5 (9%) | 1 (6.7%) | 4 (10.3%) | |
 Headache and craniofacial pain | 4 (7%) | 1 (6.7%) | 3 (7.7%) | |
 Pelvic pain | 3 (5.5%) | 1 (6.7%) | 2 (5.1%) | |
Pain medications | ||||
 Anticonvulsants | 33 (60%) | 7 (46.7%) | 24 (61.5%) | ns |
 NSAIDSc | 25 (45.5%) | 5 (33.3%) | 20 (51.30%) | |
 Acetaminophen | 22 (40%) | 5 (33.3%) | 17 (43.6%) | |
 Cannabinoids | 20 (36.4%) | 7 (46.7%) | 13 (33.3%) | |
 Opioids | 16 (29%) | 7 (46.7%) | 9 (23.1%) | |
 TCAd | 14 (25.5%) | 3 (20%) | 10 (25.6%) | |
 SNRIe | 13 (23.6%) | 3 (20%) | 10 (25.6%) | |
 SSRIf | 12 (21.8%) | 3 (20%) | 8 (20.5%) | |
 Muscle relaxants | 6 (10.9%) | 3 (20%) | 3 (7.7%) | |
 Melatonin | 5 (9.1%) | 1 (6.7%) | 3 (7.7%) | |
 Antipsychotics | 5 (9.1%) | 0 (0%) | 4 (10.3%) | |
 Benzodiazepine | 4 (7.3%) | 3 (20%) | 1 (2.6%) | |
 Zopiclone | 4 (7.3%) | 1 (6.7%) | 3 (7.7%) | |
 Triptans | 4 (7.3%) | 1 (6.7%) | 3 (7.7%) | |
 Steroids | 3 (5.5%) | 0 (0%) | 3 (7.7%) | |
 Bupropion | 2 (3.6%) | 0 (0%) | 2 (5.1%) | |
 SARIsg | 1 (1.8%) | 1 (6.7%) | 0 (0%) | |
 DMARDh | 1 (1.8%) | 0 (0%) | 1 (2.6%) | |
 Dopamine agonist | 1 (1.8%) | 0 (0%) | 1 (2.6%) | |